Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31270218 | 0.91 | L3MBTL1 (0.49) | L3MBTL1KDM4EHDAC6GRM2GLA | |
| SCHEMBL31270162 | 0.89 | L3MBTL1 (0.46) | L3MBTL1KDM4EGLAITGB3ITGA2B | |
| SCHEMBL31270285 | 0.84 | L3MBTL1 (0.52) | L3MBTL1KDM4EGLAITGB3ITGA2B | |
| SCHEMBL31270251 | 0.82 | L3MBTL1 (0.53) | L3MBTL1KDM4EGLAITGB3ITGA2B | |
| SCHEMBL31270083 | 0.82 | L3MBTL1 (0.44) | L3MBTL1KDM4EHDAC6GLAITGB3 | |
| SCHEMBL24576904 | 0.82 | L3MBTL1 (0.52) | L3MBTL1ITGB3ITGA2BALDH1A1MAPT | |
| SCHEMBL31270160 | 0.79 | L3MBTL1 (0.53) | L3MBTL1ITGB3ITGA2BALDH1A1MAPT | |
| SCHEMBL31270043 | 0.79 | L3MBTL1 (0.53) | L3MBTL1ITGB3ITGA2BALDH1A1MAPT | |
| SCHEMBL29760167 | 0.79 | ALOX15 (0.37) | MCHR1HDAC6 | |
| SCHEMBL31270233 | 0.79 | L3MBTL1 (0.47) | L3MBTL1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | claimed |
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | disclosed |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | QLi5 Therapeutics AG (DE) | 2024-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | PSMB5, PSMA5, PSMB1 | L3MBTL1 2388/4885MCHR1 4764/4885KDM4E 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.